MediciNova, Inc. (MNOV) Social Stream

Featured Post From StockTwits About MNOV

$MNOV

$MNOV


10-Q key features

Pursue the development of MN-166 (ibudilast) with NON-DILUTIVE financings.

Pursue the development of MN-001 (tipelukast) for fibrotic and other diseases.

Consider strategic partnerships with one or more leading pharmaceutical.

Blackrock, vanguard and JPM increased their position significantly. JPM today by 222% more.

something cooking? Guess, time will say. Follow for more update

https://twitter.com/pratiks77932094/status/1423476666882461701?s=21